Terms: = Prostate cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Staging
2 results:
1. Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer.
De Cicco C; Ravasi L; Zorzino L; Sandri MT; Botteri E; Verweij F; Granchi D; de Cobelli O; Paganelli G
Curr Cancer Drug Targets; 2008 May; 8(3):199-206. PubMed ID: 18473733
[TBL] [Abstract] [Full Text] [Related]
2. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.
Jung K; Nowak L; Lein M; Priem F; Schnorr D; Loening SA
Int J Cancer; 1997 Apr; 74(2):220-3. PubMed ID: 9133459
[TBL] [Abstract] [Full Text] [Related]
